Insmed Incorporated (NASDAQ:INSM) has earned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.50.
A number of analysts recently issued reports on INSM shares. Morgan Stanley set a $37.00 price target on shares of Insmed and gave the stock a “buy” rating in a report on Friday, November 1st. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Monday, November 25th. HC Wainwright restated a “buy” rating on shares of Insmed in a research report on Thursday, October 31st. ValuEngine raised shares of Insmed from a “hold” rating to a “buy” rating in a research note on Monday, November 25th. Finally, Zacks Investment Research cut Insmed from a “buy” rating to a “hold” rating in a report on Friday, September 27th.
NASDAQ:INSM traded up $0.39 during trading hours on Friday, reaching $23.36. The company had a trading volume of 667,031 shares, compared to its average volume of 1,059,539. Insmed has a 1-year low of $11.31 and a 1-year high of $33.13. The firm has a market cap of $2.06 billion, a PE ratio of -5.60 and a beta of 3.04. The business’s 50 day moving average price is $19.66 and its 200-day moving average price is $20.69. The company has a debt-to-equity ratio of 1.19, a current ratio of 6.97 and a quick ratio of 6.70.
In other news, CAO John Goll sold 25,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.80, for a total transaction of $520,000.00. Insiders own 4.95% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Point72 Hong Kong Ltd acquired a new position in shares of Insmed during the 2nd quarter worth approximately $34,000. Riverhead Capital Management LLC purchased a new position in Insmed during the second quarter worth approximately $73,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Insmed by 17.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 854 shares during the last quarter. NumerixS Investment Technologies Inc boosted its stake in Insmed by 26.5% during the second quarter. NumerixS Investment Technologies Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 1,007 shares during the last quarter. Finally, Tyers Asset Management LLC boosted its stake in Insmed by 1,002.5% during the second quarter. Tyers Asset Management LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 6,416 shares during the last quarter.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.